GLP-1s reduce hunger and “food noise,” creating space for healthier relationships with food.

Moralised narratives about the “easy way out” ignore the complex reasons people live in larger bodies.

Friends, families, and clinicians reduce harm by focusing on support and well-being, not judgment or blame.

New glucagon-like peptide-1 (GLP‑1) weight‑management medications such as Mounjaro and Wegovy represent a major shift in obesity treatment. In the United States, recent survey data suggest that about one in eight adults has taken a GLP‑1 medication, and around 6 percent are currently using one.[1] In the United Kingdom, it is estimated that nearly one in 10 adults have either recently used or are actively interested in these drugs.[2]

These medications are highly effective. Large studies of GLP-1 use show average weight losses of around 10 to 22 percent of initial body weight over 1 to 1.5 years, with many losing 20 percent or more.[3] Lots describe the impact as life‑changing. At the same time, the rapid rise in GLP‑1 use has triggered intense public, clinical, and media debate. Alongside enthusiasm, we have started to see stigmatising narratives about what it means to take these drugs.

"Cheating" and the "easy way out"

Early evidence suggests that some people using GLP‑1s experience negative........

© Psychology Today